Abstract
Podophyllotoxins, including epipodophyllotoxin derivatives, can act on a diverse array of drug targets in cancer cells and thus possess potent activity against various forms of cancer cell lines, including drug-resistant forms. Moreover, several podophyllotoxin derivatives represented by etoposide and teniposide, have already been approved for cancer therapy, demonstrating podophyllotoxin moiety as a useful pharmacophore for the discovery of novel anticancer agents. This review reports the recent advances in the exploitation of podophyllotoxin derivatives to fight against multidrug-resistant cancer cells. The mechanism of action and structure-activity relationship (SAR) studies are also highlighted.
Keywords: Podophyllotoxin, Epipodophyllotoxin, Anticancer, Multidrug resistance, Mechanism of action, Structure-activity relationship.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Recent Advances in the Application of Podophyllotoxin Derivatives to Fight Against Multidrug-Resistant Cancer Cells
Volume: 21 Issue: 19
Author(s): Qiuyan Guo and Enshe Jiang*
Affiliation:
- Institutes of Nursing and Health, Henan Medical School, Henan University, Kaifeng,China
Keywords: Podophyllotoxin, Epipodophyllotoxin, Anticancer, Multidrug resistance, Mechanism of action, Structure-activity relationship.
Abstract: Podophyllotoxins, including epipodophyllotoxin derivatives, can act on a diverse array of drug targets in cancer cells and thus possess potent activity against various forms of cancer cell lines, including drug-resistant forms. Moreover, several podophyllotoxin derivatives represented by etoposide and teniposide, have already been approved for cancer therapy, demonstrating podophyllotoxin moiety as a useful pharmacophore for the discovery of novel anticancer agents. This review reports the recent advances in the exploitation of podophyllotoxin derivatives to fight against multidrug-resistant cancer cells. The mechanism of action and structure-activity relationship (SAR) studies are also highlighted.
Export Options
About this article
Cite this article as:
Guo Qiuyan and Jiang Enshe *, Recent Advances in the Application of Podophyllotoxin Derivatives to Fight Against Multidrug-Resistant Cancer Cells, Current Topics in Medicinal Chemistry 2021; 21 (19) . https://dx.doi.org/10.2174/1568026621666210113163327
DOI https://dx.doi.org/10.2174/1568026621666210113163327 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function
Current Pharmaceutical Design Myelodysplastic/Myeloproliferative Neoplasms
Current Cancer Therapy Reviews Synthesis and Enzymological Characterization of Some 2-(Substitutedphenylamino) quinazolin-4(3H)-one Derivatives as Potent α-Glucosidase Inhibitors In Vitro
Letters in Drug Design & Discovery Genetic and Epigenetic Regulation of Phosphoinositide 3-kinase Isoforms
Current Pharmaceutical Design Future Prospects for Targeted Alpha Therapy
Current Radiopharmaceuticals Anticancer Alkylphospholipids: Mechanisms of Action, Cellular Sensitivity and Resistance, and Clinical Prospects
Current Pharmaceutical Design Recent Advances and Developments in Treatment Strategies Against Pancreatic Cancer
Current Clinical Pharmacology The Molecular Machinery Regulating Apoptosis Signal Transduction and its Implication in Human Physiology and Pathophysiologies
Current Molecular Medicine An Integrative Informatics Approach to Explain the Mechanism of Action of N1-(Anthraquinon-2-yl) Amidrazones as BCR/ABL Inhibitors
Current Computer-Aided Drug Design Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design Design of New Drug Molecules to be Used in Reversing Multidrug Resistance in Cancer Cells
Current Cancer Drug Targets Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Bench to Bedside Targeting of FLT3 in Acute Leukemia
Current Drug Targets Summary of Information on the Effects of Ionizing and Non-ionizing Radiation on Cytochrome P450 and Other Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification
Current Pharmaceutical Design Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics On the Generation of Novel Anticancer Drugs by Recombinant DNA Technology: The Use of Combinatorial Biosynthesis to Produce Novel Drugs
Combinatorial Chemistry & High Throughput Screening